| Literature DB >> 36233547 |
Shin Yagi1, Yusuke Kurita1, Takamitsu Sato1, Sho Hasegawa1, Kunihiro Hosono1, Noritoshi Kobayashi2, Itaru Endo3, Yusuke Saigusa4, Kensuke Kubota1, Atsushi Nakajima1.
Abstract
BACKGROUND ANDEntities:
Keywords: EUS-guided biliary drainage; biliary obstruction; hepaticogastrostomy; interventional EUS
Year: 2022 PMID: 36233547 PMCID: PMC9571885 DOI: 10.3390/jcm11195681
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Figure 1(a) shows the fine-gauge balloon catheter (REN biliary dilation catheter; KANEKA, Osaka, Japan). The tip of this balloon catheter is tapered and only 3 Fr wide. This fine-gauge balloon catheter is compatible with 0.025-inch guidewire and is coaxial with guidewire. In this study, catheters with a balloon diameter of 4 mm or 6 mm were used; (b) shows an ultra-tapered mechanical (bougie) dilator (ES dilator; Zeon Medical Co., Ltd., Tokyo, Japan). The tip of the ES dilator is 2.5 Fr, and the step between the catheter tip and guidewire is small. The diameter of the ES dilator is 7 Fr; (c) shows a bougie dilator (Soehendra Biliary Dilation Catheter; Cook Japan, Tokyo, Japan). A Soehendra Biliary Dilation Catheter with a 4 Fr tip and a 7 Fr catheter diameter was used for initial dilation. A Soehendra Biliary Dilation Catheter with a 6 Fr tip and a 9 Fr catheter diameter was used only for additional dilation.
Figure 2Radiographic images. (a) Puncture the bile duct; (b) After aspirating bile juice or contrast was used to confirm that it was a bile duct, a guidewire was inserted into the bile duct; (c) Tract dilation of a fine-gauge balloon catheter. (d) An SEMS was placed.
Figure 3Flow diagram showing the number of patients.
Patient characteristics.
| Total | BD Group | Non-BD Group |
| |
|---|---|---|---|---|
| No. of cases (%) | ||||
| Age, years, median (range) | 69 (36–84) | 69 (56–83) | 69 (36–84) | 0.685 |
| Sex (%) | 0.506 | |||
| Male | 24 (63.2%) | 12 (70.6%) | 12 (57.1%) | |
| Female | 14 (36.8%) | 5 (29.4%) | 9 (42.9%) | |
| Etiology of biliary obstruction (%) | 0.259 | |||
| Pancreatic cancer | 18 (47.4%) | 10 (58.8%) | 8 (38.1%) | |
| Biliary cancer | 9 (23.7%) | 2 (11.8%) | 7 (33.3%) | |
| Other | 11 (28.9%) | 5 (29.4%) | 6 (28.6%) | |
| Biliary obstruction (%) | 0.062 | |||
| Distal | 26 (68.4%) | 12 (70.6%) | 14 (66.7%) | |
| Hilar | 9 (23.7%) | 2 (11.8%) | 7 (33.3%) | |
| Postoperative anastomosis | 3 (7.9%) | 3 (17.6%) | 0 |
BD group: balloon dilation group, Non-BD group: non-balloon dilation group, EUS-2 HGS: endoscopic ultrasound-guided hepaticogastrostomy.
Outcomes of EUS-HGS between BD groups or non-BD groups.
| Total | BD Group | Non-BD Group |
| |
|---|---|---|---|---|
| No. of cases (%) | ||||
| Procedure time, min, median (range) | 35.5 (17–80) | 37 (19–80) | 32 (17–60) | 0.601 |
| Diameter of bile duct of puncture site, mm, median (range) | 6 (4–15) | 5.8 (4–9) | 6 (4–15) | 0.149 |
| Puncture site (%) | 0.197 | |||
| B2 | 6 (15.8%) | 1 (5.9%) | 5 (23.8%) | |
| B3 | 32 (84.2%) | 16 (94.1%) | 16 (76.2%) | |
| Initial dilation (%) | - | |||
| Balloon dilator | ||||
| REN 4 mm diameter | 14 (36.8%) | 14 (82.4%) | ||
| REN 6 mm diameter | 3 (7.9%) | 3 (17.6%) | ||
| Bougie dilator | ||||
| ES dilator (7 Fr) | 13 (34.2%) | 13 (85.7%) | ||
| Soehendra (7 Fr) | 3 (7.9%) | 3 (14.3%) | ||
| Stenting success rate after initial dilation (%) | 84.2% (32/38) | 100% (17/17) | 71.4% (15/21) | 0.024 |
| Additional dilation (%) | 6 (15.8%) | 0 | 6 (28.6%) | 0.024 |
| Balloon dilator | ||||
| REN 4 mm diameter | 4 (10.5%) | 0 | 4 (19.0%) | |
| Bougie dilator | ||||
| Soehendra (9 Fr) | 2 (5.3%) | 0 | 2 (9.5%) | |
| Adverse events (%) | ||||
| Peritonitis | 4 (10.5%) | 1 (5.9%) | 3 (14.3%) | 0.613 |
| Biloma | 1 (2.6%) | 0 | 1 (4.8%) | 1.000 |
| Bleeding | 0 | 0 | 0 | - |
| Stent migration | 0 | 0 | 0 | - |
EUS-HGS: EUS-guided hepaticogastrostomy, BD group: balloon dilation group, non-BD group: non-balloon dilation group, B2: bile duct of segment 2 of the liver, B3: bile duct of segment 3 of the liver, SEMS: self-expandable metal stent.
Multivariate analysis of factors influencing the stenting success rate after initial dilation.
| Variable | Stenting Success Rate after Initial Dilation (%) | OR | 95% CI |
| |
|---|---|---|---|---|---|
| Biliary obstruction | Hilar | 77.8% (7/9) | 0.266 | 0.022–1.991 | 0.202 |
| Non hilar | 86.2% (25/29) | ||||
| Puncture site | B3 | 79.5% (26/32) | 0.109 | 0.0006–1.539 | 0.114 |
| B2 | 100.0% (6/6) | ||||
| Diameter of bile duct of puncture site | ≥5 mm | 83.3% (25/30) | 0.440 | 0.023–3.952 | 0.487 |
| <5 mm | 87.5% (7/8) | ||||
| Type of dilation | Non-BD group | 71.4% (15/21) | 0.060 | 0.0004–0.657 | 0.013 |
| BD group | 100.0% (17/17) |
OR: odds ratio, CI: confidence interval, BD group: balloon dilation group, non-BD group: non-balloon dilation group, B2: bile duct of segment 2 of the liver, B3: bile duct of segment 3 of the liver, SEMS: self-expandable metal stent.